Misoprostol: an effective agent for cervical ripening and labor induction

Area of Science:

• Obstetrics and Gynecology
• Reproductive Medicine
• Pharmacology

Background:

• Cervical ripening and labor induction are critical interventions in obstetrics.
• Prostaglandins are commonly used agents for these procedures.
• Comparing different prostaglandin formulations and administration routes is essential for optimizing patient care.

Purpose of the Study:

• To compare the safety and efficacy of intravaginal misoprostol versus intracervical prostaglandin E2 gel (dinoprostone) for preinduction cervical ripening and labor induction.
• To evaluate differences in labor duration, need for augmentation, delivery route, and complication rates between the two agents.

Main Methods:

• A randomized controlled trial involving 276 patients with indications for labor induction and unfavorable cervices.
• Patients were assigned to receive either intravaginal misoprostol (25 mcg every 3 hours) or intracervical dinoprostone (0.5 mg every 6 hours).
• Medication was withheld based on specific clinical criteria, including spontaneous rupture of membranes or active labor.

Main Results:

• The average interval from induction start to vaginal delivery was significantly shorter with misoprostol (1323.0 min) compared to dinoprostone (1532.4 min).
• Oxytocin augmentation was required less frequently in the misoprostol group (45.7%) than in the dinoprostone group (72.6%).
• No significant differences were observed in delivery routes or complication rates (uterine tachysystole, meconium passage) between the groups.

Conclusions:

• Intravaginal misoprostol is an effective alternative to intracervical dinoprostone for cervical ripening and labor induction.
• Misoprostol demonstrated comparable safety outcomes to dinoprostone.
• The significantly lower cost of misoprostol makes it a more economical option for labor induction.